Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 15/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.60 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.60 |
| ▸ | G6PD | P11413 | 1/20 | 0.60 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.60 |
| ▸ | METAP2 | P50579 | 1/20 | 0.60 |
| ▸ | METAP1 | P53582 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972869 | 0.83 | SLC40A1 (1.00) | SLC40A1TDP1AGTR1GLO1G6PD | |
| SCHEMBL11973640 | 0.82 | SLC40A1 (1.00) | SLC40A1TDP1AGTR1GLO1G6PD | |
| SCHEMBL11973010 | 0.82 | SLC40A1 (1.00) | SLC40A1TDP1AGTR1GLO1G6PD | |
| SCHEMBL11973384 | 0.80 | SLC40A1 (1.00) | SLC40A1TDP1AGTR1GLO1G6PD | |
| SCHEMBL11973715 | 0.80 | SLC40A1 (1.00) | SLC40A1TDP1AGTR1GLO1G6PD | |
| SCHEMBL21537701 | 0.78 | SLC40A1 (0.63) | SLC40A1TDP1GLO1MMP2ALDH1A1 | |
| SCHEMBL442367 | 0.76 | SLC40A1 (1.00) | SLC40A1TDP1AGTR1GLO1G6PD | |
| SCHEMBL7746129 | 0.74 | SLC40A1 (0.97) | SLC40A1TDP1AGTR1GLO1G6PD | |
| SCHEMBL11973488 | 0.73 | SLC40A1 (1.00) | SLC40A1TDP1AGTR1GLO1G6PD | |
| SCHEMBL12972046 | 0.72 | SLC40A1 (0.74) | SLC40A1TDP1AGTR1GLO1G6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| CN-103492028-A | Novel sulfonaminoquinoline hepcidin antagonists | VIFOR INT AG | 2014-01-01 | — | — | CN | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885TDP1 4862/4885AGTR1 2153/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885TDP1 4862/4885AGTR1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.